ATO-101 for Returning Bladder Cancer Before Surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, ATO-101, in patients whose non-muscle-invasive bladder cancer has returned after standard treatment (BCG therapy, with or without mitomycin). The goal is to see if it can help before considering radical surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to care for yourself (performance status 0 or 1).
- Your bladder cancer came back after BCG therapy (with or without mitomycin), and surgery is being considered.
- You have papillary tumors seen on a bladder scope and confirmed by biopsy.
- Your cancer is histologically confirmed as non-muscle-invasive.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use birth control for at least 3 months after getting ATO-101.
- Your organ function (kidney, liver, etc.) must be good enough for safe drug use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests whether using a patient's own tumor cells in lab-made clusters (PTCs) can help guide chemotherapy before bladder removal surgery for muscle-invasive bladder cancer. If you qualify, you'll receive personalized treatment followed by surgery.
This trial tests a new drug called 9MW2821 for people with high-risk bladder cancer that hasn't grown into the bladder muscle. It's for those who have already tried other treatments that didn't work or who can't have standard therapy.
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
This trial tests atezolizumab (an immune therapy) given before surgery for certain bladder or upper urinary tract cancers. The goal is to shrink or control the cancer early and improve outcomes after curative surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.